India, Sept. 4 -- Pyxis Oncology, Inc. (PYXS), a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers, recently announced that Interim Chief Executive Officer and Director Tom Civik will participate in fireside chats at three upcoming healthcare and investment conferences.
The company will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston on September 10, 2026.
Pyxis will also participate in the 2026 Cantor Global Healthcare Conference in New York on September 11 followed by the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14.
Clinical Pipeline:
Pyxis' lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug co...